The Federal Trade Commission’s (FTC) oversight role in the pharmaceutical market is critical to the health of patients and the health care system. Aaron Kesselheim, MD, JD, MPH, and JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, discuss the FTC’s policies and legal actions related to alleged misconduct, consolidation, and anticompetitive behavior in the pharmaceutical market. Related Content:
JAMA Clinical Reviews